"Our mission is to expand the adoption of cardiac MRI and CT solutions, enabling precise and efficient heart disease diagnosis from advanced general hospitals to routine health checkups," said CEO Pan Ki Kim.
On the 25th, CEO Pan Ki Kim shared the inspiration behind Phantomics: "While MRI equipment provides measurable indicators reflecting cellular environments, discrepancies in these values among devices have been a significant challenge. By correcting these measurement errors through AI and automating the process, we can greatly enhance clinical applicability."
This vision led to the creation of two key solutions:
- Myomics: Automatically adjusts MRI images using AI, allowing clinicians to diagnose conditions such as myocarditis and heart failure accurately within a short 20-minute scan.
- Angiomics: Analyzes CT scans in emergency rooms to quickly determine if arterial blockage exceeds 50%, enabling life-saving treatment within the golden hour.
"MRI machines in hospitals often go underutilized due to long scanning and interpretation times," Kim noted. "With Myomics, the analysis is automated, and scanning times are drastically reduced from 90 minutes to 20 minutes, allowing for efficient operation while ensuring patients receive swift and accurate diagnoses."
The solutions have already been adopted by over 20 hospitals in Korea and 13 international hospitals, demonstrating their potential to improve awareness and accessibility of cardiac MRI.
Headquartered in Magok, Seoul, Phantomics has established a branch in Boston's CIC Center and actively participates in global R&D initiatives. Collaborations are underway with partners in France, Spain, and other European countries.
In Asia, Phantomics is pursuing regulatory approvals and joint projects with Taiwan, Thailand, Malaysia, Japan, and Singapore. In Taiwan, for instance, the company is applying real patient data to refine its solutions.
Phantomics received the CES 2024 Innovation Award for Myomics in digital healthcare and the FIX Innovation Awards for Outstanding Technology in October. The company also secured Series A funding in 2022, highlighting its growth potential in medical AI.
"Although the investment market remains challenging, the global cardiovascular field is experiencing rapid growth," Kim said. "We aim to penetrate domestic and international cardiac care markets with Myomics and Angiomics before expanding to other organs."
Phantomics aspires to be a "virtual fellow" for healthcare providers, offering automated, AI-powered insights to assist medical staff. The company's name combines "phantom" and "omics" to reflect its role as a virtual assistant that provides essential information seamlessly.
"Cardiovascular diseases are critical challenges not only for Korea but for the entire world," Kim emphasized. "By standardizing cardiac MRI and CT with AI, Phantomics aims to lower barriers, creating a win-win ecosystem for all stakeholders."
Read Article
"Our mission is to expand the adoption of cardiac MRI and CT solutions, enabling precise and efficient heart disease diagnosis from advanced general hospitals to routine health checkups," said CEO Pan Ki Kim.
On the 25th, CEO Pan Ki Kim shared the inspiration behind Phantomics: "While MRI equipment provides measurable indicators reflecting cellular environments, discrepancies in these values among devices have been a significant challenge. By correcting these measurement errors through AI and automating the process, we can greatly enhance clinical applicability."
This vision led to the creation of two key solutions:
"MRI machines in hospitals often go underutilized due to long scanning and interpretation times," Kim noted. "With Myomics, the analysis is automated, and scanning times are drastically reduced from 90 minutes to 20 minutes, allowing for efficient operation while ensuring patients receive swift and accurate diagnoses."
The solutions have already been adopted by over 20 hospitals in Korea and 13 international hospitals, demonstrating their potential to improve awareness and accessibility of cardiac MRI.
Headquartered in Magok, Seoul, Phantomics has established a branch in Boston's CIC Center and actively participates in global R&D initiatives. Collaborations are underway with partners in France, Spain, and other European countries.
In Asia, Phantomics is pursuing regulatory approvals and joint projects with Taiwan, Thailand, Malaysia, Japan, and Singapore. In Taiwan, for instance, the company is applying real patient data to refine its solutions.
Phantomics received the CES 2024 Innovation Award for Myomics in digital healthcare and the FIX Innovation Awards for Outstanding Technology in October. The company also secured Series A funding in 2022, highlighting its growth potential in medical AI.
"Although the investment market remains challenging, the global cardiovascular field is experiencing rapid growth," Kim said. "We aim to penetrate domestic and international cardiac care markets with Myomics and Angiomics before expanding to other organs."
Phantomics aspires to be a "virtual fellow" for healthcare providers, offering automated, AI-powered insights to assist medical staff. The company's name combines "phantom" and "omics" to reflect its role as a virtual assistant that provides essential information seamlessly.
"Cardiovascular diseases are critical challenges not only for Korea but for the entire world," Kim emphasized. "By standardizing cardiac MRI and CT with AI, Phantomics aims to lower barriers, creating a win-win ecosystem for all stakeholders."
Read Article